var data={"title":"Pentastarch (Hydroxyethyl starch 200/0.5; Pentaspan) (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pentastarch (Hydroxyethyl starch 200/0.5; Pentaspan) (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6747?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207901\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pentaspan [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207907\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Plasma Volume Expander, Colloid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207889\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12806127\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infusion, premixed in NS:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pentaspan: 10% (250 mL, 500 mL) [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12806126\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US; All Canadian dosage forms have been discontinued for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207896\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adjunctive treatment in the management of shock</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>The Surviving Sepsis Campaign International Guidelines for the Management of Severe Sepsis and Septic Shock recommends <i>against</i> the use of hydroxyethyl starch (eg, pentastarch) for fluid resuscitation of severe sepsis and septic shock (Rhodes 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805815\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, edema, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, chills, dizziness, fatigue, headache, insomnia, malaise, paresthesia, shakiness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Weight gain (temporary)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, increased serum amylase, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Blood coagulation disorder, hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction, anaphylaxis, hypersensitivity reaction (includes hypotension, urticaria, wheezing)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Nasal congestion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Renal disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805661\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to hydroxyethyl starch or any component of the formulation; bleeding disorders; congestive heart failure where volume overload is a concern; oliguria or anuria not related to hypovolemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805724\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Avoid use in patients undergoing open heart surgery in association with cardiopulmonary bypass. HES solutions have been associated with excess bleeding in these patients. If used in other patient populations, discontinue use of HES at the first sign of coagulopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid overload: Administration can cause fluid overload; use with caution in patients at risk from overexpansion of blood volume (eg, very young patients, aged patients, or those with heart failure).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic: Large volumes of pentastarch may cause reduction in hemoglobin concentration, coagulation factors, and other plasma proteins due to hemodilution; coagulation may be impaired (eg, prolonged PT, PTT, and clotting times) and a transient prolongation of bleeding time may be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Anaphylactic/anaphylactoid reactions have been reported; discontinue use immediately with signs of hypersensitivity and administer appropriate therapy. Patients allergic to corn may be allergic to pentastarch.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal failure: <b>HES solutions have been associated with renal injury requiring renal replacement therapy in critically-ill patients (Reinhart, 2012); avoid use in critically-ill adult patients, including those with sepsis and those admitted to the ICU. If used in patients who are not critically ill, avoid use in patients with pre-existing renal dysfunction and discontinue use at the first sign of renal injury. </b> Since the need for renal replacement therapy has been reported up to 90 days after HES administration, continue to monitor renal function in all patients for at least 90 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Treatment-related mortality: <b>Avoid use in critically-ill adult patients, including those with sepsis and those admitted to the ICU. HES solutions have been associated with an increased risk of mortality in the critically ill</b> (Brunkhorst, 2008; Perel, 2011; Perner, 2012; Zarychanski, 2009). The Society of Critical Care Medicine (SCCM) also recommends against the use of HES solutions for fluid resuscitation of severe sepsis and septic shock; crystalloids (eg, sodium chloride, Ringer's lactate) are recommended as the fluid of choice for initial resuscitation and subsequent intravascular volume replacement (Rhodes 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders (eg, von Willebrand&rsquo;s disease): Use caution in severe bleeding disorders; may increase the risk of more bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Use with caution in heart failure patients; monitor closely for fluid overload.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with mild-to-moderate hepatic impairment. Avoid use in patients with severe hepatic impairment. May result in further reduction of coagulation factors in patients with ongoing hepatic impairment, increasing the risk of bleeding. Use with caution in patients with a history of liver disease due to elevations of indirect bilirubin (significance unknown).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; fluid status including urine output should be monitored closely. Use is contraindicated with oliguria or anuria not related to hypovolemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not a substitute for red blood cells or coagulation factors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299845\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222215\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10203&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Arbekacin: Pentastarch may enhance the nephrotoxic effect of Arbekacin. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805680\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805681\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Excretion in human breast milk is unknown; use caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12806093\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate, CVP, capillary refill time, cardiac index; if pulmonary artery catheter in place, monitor PCWP, SVR, and PVR; urine output, hemoglobin, hematocrit, serum electrolytes, renal function (continue to monitor for at least 90 days after administration), coagulation parameters</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805851\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Produces plasma volume expansion by virtue of its highly colloidal starch structure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12805853\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Volume expansion: Within 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 18-24 hours (improves hemodynamic status for 12-18 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~2 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~70% within 24 hours; ~80% within 1 week)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207898\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>HAES-steril (GB, NO);</li>\n      <li>Haes-Steril (SA, TW);</li>\n      <li>Pentarch (KR);</li>\n      <li>Pentaspan (KR);</li>\n      <li>Voluven (AU, BH, CY, QA, SA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Brunkhorst FM, Engel C, Bloos F, et al, &quot;Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis,&quot; <i>N Engl J Med</i>, 2008, 358(2):125-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/18184958/pubmed\" target=\"_blank\" id=\"18184958\">18184958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jungheinrich C and Neff TA, &quot;Pharmacokinetics of Hydroxyethyl Starch,&quot; <i>Clin Pharmacokinet</i>, 2005;44(7):681-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/15966753/pubmed\" target=\"_blank\" id=\"15966753\">15966753</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perel P and Roberts I, &ldquo;Colloids versus Crystalloids for Fluid Resuscitation in Critically Ill Patients,&rdquo; <i>Cochrane Database Syst Rev</i>, 2012, 6:CD000567.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/22696320/pubmed\" target=\"_blank\" id=\"22696320\">22696320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perner A, Haase N, Guttormsen AB, et al, &ldquo;Hydroxyethyl Starch 130/0.4 versus Ringer&rsquo;s Acetate in Severe Sepsis [published correction appears in <i>N Engl J Med</i>. 2012;367(5):481]. <i>N Engl J Med</i>. 2012;367(2):124-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/22738085/pubmed\" target=\"_blank\" id=\"22738085\">22738085</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reinhart K, Perner A, Sprung CL, et al, &ldquo;Consensus Statement of the ESICM Task Force on Colloid Volume Therapy in Critically Ill Patients,&rdquo; <i>Intensive Care Med</i>, 2012, 38(3):368-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/22323076/pubmed\" target=\"_blank\" id=\"22323076\">22323076</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/28101605/pubmed\" target=\"_blank\" id=\"28101605\">28101605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strauss RG, Pennell BJ, and Stump DC, &quot;A Randomized, Blinded Trial Comparing the Hemostatic Effects of Pentastarch Versus Hetastarch,&quot; <i>Transfusion</i>, 2002, 42(1):27-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/11896309/pubmed\" target=\"_blank\" id=\"11896309\">11896309</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zarychanski R, Turgeon AF, Fergusson DA, et al, &ldquo;Renal Outcomes and Mortality Following Hydroxyethyl Starch Resuscitation of Critically Ill Patients: Systematic Review and Meta-Analysis of Randomized Trials&rdquo; <b>ATTENTION:</b> The analysis and conclusions of this article are being revised by the authors. This is due to the journal Anesthesia and Analgesia's retraction of a paper by Dr. Joachim Boldt, an author in seven of the studies analyzed in this review. As such, the editors of Open Medicine recommend interpreting this review with extreme caution until Zarychanski et al. publish a new analysis and interpretation in Open Medicine. For more information, see Anesthesia and Analgesia's press release. <i>Open Med</i>, 2009, 3(4):e196-209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/21688756/pubmed\" target=\"_blank\" id=\"21688756\">21688756</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10203 Version 69.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F207901\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F207907\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F207889\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F12806127\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F12806126\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F207896\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F12805815\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F12805661\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F12805724\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299845\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222215\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F12805680\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F12805681\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F12806093\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F12805851\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F12805853\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F207898\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10203|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}